In the last trading week, investing in penny stocks tied to digital payment startups posted average price increases of 6.8% amid news of series-A funding rounds. Institutional tracking shows a marginal rise in small cap ETF allocations toward these names. In other words, it seems likely that Opendoor's near-term financial performance as a business could be volatile, if not downright ugly, reading. Unless the new CEO can keep investors excited, which will most likely be driven by ideas and not financial results, the stock could have trouble sustaining its current levels. Teknova’s product lines have found application in a wide range of established and emerging fields, including such hot-button fields as cell and gene therapy, mRNA therapeutics, synthetic biology, and genomics. The company has proprietary manufacturing processes designed to deliver high-quality, made-to-order bioscience products at scale and on short turnaround times. Teknova boasts that it can fill orders at all scales and at all stages of development, from research to commercialization. Rare biotech penny stock announcements of Phase II trial success have fueled aggressive volume spikes, prompting swing traders to re-enter positions. This underscores the risk-reward character of investing in penny stocks.